Improving engraftment and immune reconstitution in umbilical cord blood transplantation

Frontiers in Immunology

Volumn 5, Issue FEB, 2014, Pages

  Danby, Robert ^a,b,c   Rocha, Vanderson ^a,b,c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Engraftment; Hematopoietic stem cells; Immune reconstitution; Transplantation; Umbilical cord blood

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 7; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; DONOR; ENGRAFTMENT; HISTOCOMPATIBILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; MYCOSIS; NATURAL KILLER CELL; NEUTROPENIA; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TISSUE TRANSPLANTATION; UMBILICAL CORD BLOOD TRANSPLANTATION; VIRUS INFECTION;

EID: 84895509942     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00068     Document Type: Review

References (226)

1. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med (1989) 321(17):1174-8. doi: 10.1056/NEJM198910263211707.
2. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood (2013) 122(4):491-8. doi:10.1182/blood-2013-02-453175.
3. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med (1997) 337(6):373-81. doi:10.1056/NEJM199708073370602.
4. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood (2001) 97(10):2962-71. doi:10.1182/blood.V97.10.2962.
5. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med (2004) 351(22):2276-85. doi:10.1056/NEJMoa041469.
6. Rocha V, Gluckman E, Eurocord-Netcord R, European B, Marrow Transplant G. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft-and transplantation-related factors. Br J Haematol (2009) 147(2):262-74. doi:10.1111/j.1365-2141.2009.07883.x.
7. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med (1998) 339(22):1565-77. doi:10.1056/NEJM199811263392201.
8. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med (2004) 351(22):2265-75. doi:10.1056/NEJMoa041276.
9. Szabolcs P, Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy (2007) 9(2):111-22. doi:10.1080/14653240701231014.
10. Rocha V, Broxmeyer HE. New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant (2010) 16(1 Suppl):S126-32. doi:10.1016/j.bbmt.2009.11.001.
11. Kaminski BA, Kadereit S, Miller RE, Leahy P, Stein KR, Topa DA, et al. Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation. Blood (2003) 102(13):4608-17. doi:10.1182/blood-2003-05-1732.
12. Chen L, Cohen AC, Lewis DB. Impaired allogeneic activation and T-helper 1 differentiation of human cord blood naive CD4 T cells. Biol Blood Marrow Transplant (2006) 12(2):160-71. doi:10.1016/j.bbmt.2005.10.027.
13. Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol (2011) 79(2):112-26. doi:10.1016/j.critrevonc.2010.07.009.
14. Tolar J, Hippen KL, Blazar BR. Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol (2009) 147(2):200-6. doi:10.1111/j.1365-2141.2009.07781.x.
15. Mayer E, Bannert C, Gruber S, Klunker S, Spittler A, Akdis CA, et al. Cord blood derived CD4+ CD25(high) T cells become functional regulatory T cells upon antigen encounter. PLoS One (2012) 7(1):e29355. doi:10.1371/journal.pone.0029355.
16. Drohan L, Harding JJ, Holm B, Cordoba-Tongson E, Dekker CL, Holmes T, et al. Selective developmental defects of cord blood antigen-presenting cell subsets. Hum Immunol (2004) 65(11):1356-69. doi:10.1016/j.humimm.2004.09.011.
17. Yamazaki S, Inaba K, Tarbell KV, Steinman RM. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol Rev (2006) 212:314-29. doi:10.1111/j.0105-2896.2006.00422.x.
18. Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 32(4):397-407. doi:10.1016/j.exphem.2004.01.002.
19. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood (2010) 115(19):3861-8. doi:10.1182/blood-2009-12-234096.
20. Petropoulou AD, Rocha V. Risk factors and options to improve engraftment in unrelated cord blood transplantation. Stem Cells Int (2011) 2011:610514. doi:10.4061/2011/610514.
21. Niehues T, Rocha V, Filipovich AH, Chan KW, Porcher R, Michel G, et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children-a Eurocord analysis. Br J Haematol (2001) 114(1):42-8. doi:10.1046/j.1365-2141.2001.02900.x.
22. Verneris MR, Miller JS. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol (2009) 147(2):185-91. doi:10.1111/j.1365-2141.2009.07768.x.
23. Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol (2012) 73(3):248-57. doi:10.1016/j.humimm.2011.12.015.
24. Gaddy J, Broxmeyer HE. Cord blood CD16+56-cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol (1997) 180(2):132-42. doi:10.1006/cimm.1997.1175.
25. Ruggeri A, Peffault de Latour R, Carmagnat M, Clave E, Douay C, Larghero J, et al. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl Infect Dis (2011) 13(5):456-65. doi:10.1111/j.1399-3062.2011.00632.x.
26. Somers JA, Brand A, van Hensbergen Y, Mulder A, Oudshoorn M, Sintnicolaas K, et al. Double umbilical cord blood transplantation: a study of early engraftment kinetics in leukocyte subsets using HLA-specific monoclonal antibodies. Biol Blood Marrow Transplant (2013) 19(2):266-73. doi:10.1016/j.bbmt.2012.09.022.
27. Tanaka J, Sugita J, Asanuma S, Arita K, Shono Y, Kikutchi M, et al. Increased number of CD16(+)CD56(dim) NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation. Hum Immunol (2009) 70(9):701-5. doi:10.1016/j.humimm.2009.06.002.
28. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood (2007) 110(13):4543-51. doi:10.1182/blood-2007-05-092130.
29. Kanda J, Chiou LW, Szabolcs P, Sempowski GD, Rizzieri DA, Long GD, et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 18(11):1664-76.e1. doi:10.1016/j.bbmt.2012.06.005.
30. Escalon MP, Komanduri KV. Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution. Curr Opin Oncol (2010) 22(2):122-9. doi:10.1097/CCO.0b013e328335a56e.
31. Hollander GA, Krenger W, Blazar BR. Emerging strategies to boost thymic function. Curr Opin Pharmacol (2010) 10(4):443-53. doi:10.1016/j.coph.2010.04.008.
32. Talvensaari K, Clave E, Douay C, Rabian C, Garderet L, Busson M, et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood (2002) 99(4):1458-64. doi:10.1182/blood.V99.4.1458.
33. Clave E, Lisini D, Douay C, Giorgiani G, Busson M, Zecca M, et al. Thymic function recovery after unrelated donor cord blood or T-cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse. Front Immunol (2013) 4:54. doi:10.3389/fimmu.2013.00054.
34. Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood (2012) 119(12):2949-55. doi:10.1182/blood-2011-06-363572.
35. Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, Boyer O, et al. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol (2008) 127(1):14-25. doi:10.1016/j.clim.2007.11.013.
36. Beck JC, Wagner JE, DeFor TE, Brunstein CG, Schleiss MR, Young JA, et al. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant (2010) 16(2):215-22. doi:10.1016/j.bbmt.2009.09.019.
37. Merindol N, Salem Fourati I, Brito RM, Grenier AJ, Charrier E, Cordeiro P, et al. Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation. J Immunol (2012) 189(10):5016-28. doi:10.4049/jimmunol.1201759.
38. McGoldrick SM, Bleakley ME, Guerrero A, Turtle CJ, Yamamoto TN, Pereira SE, et al. Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo. Blood (2013) 121(14):2796-803. doi:10.1182/blood-2012-09-453720.
39. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood (2006) 108(8):2874-80. doi:10.1182/blood-2006-03-011791.
40. Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, et al. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Societe Francaise de Greffe de Moelle-Therapie Cellulaire collaborative study. Bone Marrow Transplant (2013) 48(2):253-6. doi:10.1038/bmt.2012.117.
41. Vandenbosch K, Ovetchkine P, Champagne MA, Haddad E, Alexandrov L, Duval M. Varicella-zoster virus disease is more frequent after cord blood than after bone marrow transplantation. Biol Blood Marrow Transplant (2008) 14(8):867-71. doi:10.1016/j.bbmt.2008.05.006.
42. Scheurer ME, Pritchett JC, Amirian ES, Zemke NR, Lusso P, Ljungman P. HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis. Bone Marrow Transplant (2013) 48(4):574-80. doi:10.1038/bmt.2012.180.
43. Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica (2010) 95(7):1183-90. doi:10.3324/haematol.2009.016758.
44. Parody R, Martino R, Rovira M, Vazquez L, Vazquez MJ, de la Camara R, et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant (2006) 12(7):734-48. doi:10.1016/j.bbmt.2006.03.007.
45. Barker JN, Hough RE, van Burik JA, DeFor TE, MacMillan ML, O'Brien MR, et al. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol Blood Marrow Transplant (2005) 11(5):362-70. doi:10.1016/j.bbmt.2005.02.004.
46. Barker JN, Weisdorf DJ, Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med (2001) 344(24):1870-1. doi:10.1056/NEJM200106143442417.
47. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 110(8):3064-70. doi:10.1182/blood-2007-04-067215.
48. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2005) 105(3):1343-7. doi:10.1182/blood-2004-07-2717.
49. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood (2010) 116(22):4693-9. doi:10.1182/blood-2010-05-285304.
50. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood (2009) 114(19):4293-9. doi:10.1182/blood-2009-05-220525.
51. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med (2012) 367(24):2305-15. doi:10.1056/NEJMoa1207285.
52. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant (2002) 8(7):368-76. doi:10.1053/bbmt.2002.v8.pm12171483.
53. Levac K, Karanu F, Bhatia M. Identification of growth factor conditions that reduce ex vivo cord blood progenitor expansion but do not alter human repopulating cell function in vivo. Haematologica (2005) 90(2):166-72.
54. Bordeaux-Rego P, Luzo A, Costa FF, Olalla Saad ST, Crosara-Alberto DP. Both interleukin-3 and interleukin-6 are necessary for better ex vivo expansion of CD133+ cells from umbilical cord blood. Stem Cells Dev (2010) 19(3):413-22. doi:10.1089/scd.2009.0098.
55. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant (2008) 41(9):771-8. doi:10.1038/sj.bmt.1705979.
56. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med (2010) 16(2):232-6. doi:10.1038/nm.2080.
57. Robinson S, Niu T, de Lima M, Ng J, Yang H, McMannis J, et al. Ex vivo expansion of umbilical cord blood. Cytotherapy (2005) 7(3):243-50. doi:10.1080/14653240510027172.
58. Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood (2003) 101(12):5061-7. doi:10.1182/blood-2001-12-0290.
59. Astori G, Adami V, Mambrini G, Bigi L, Cilli M, Facchini A, et al. Evaluation of ex vivo expansion and engraftment in NOD-SCID mice of umbilical cord blood CD34+ cells using the DIDECO "Pluricell System". Bone Marrow Transplant (2005) 35(11):1101-6. doi:10.1038/sj.bmt.1704964.
60. Sebrango A, Vicuna I, de Laiglesia A, Millan I, Bautista G, Martin-Donaire T, et al. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes. Best Pract Res Clin Haematol (2010) 23(2):259-74. doi:10.1016/j.beha.2010.05.002.
61. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood (2011) 118(24):6438-45. doi:10.1182/blood-2011-08-372508.
62. Frassoni F, Gualandi F, Podesta M, Raiola AM, Ibatici A, Piaggio G, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol (2008) 9(9):831-9. doi:10.1016/S1470-2045(08)70180-3.
63. Okada M, Yoshihara S, Taniguchi K, Kaida K, Ikegame K, Kato R, et al. Intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning treatment: a phase I study. Biol Blood Marrow Transplant (2012) 18(4):633-9. doi:10.1016/j.bbmt.2011.08.010.
64. Saglio F, Berger M, Vassallo E, Nesi F, Gunetti M, Fazio L, et al. Intrabone cord blood hematopoietic stem cell transplantation in a subset of very high-risk pediatric patients: a safety and feasibility pilot study. J Pediatr Hematol Oncol (2012) 34(5):359-63. doi:10.1097/MPH.0b013e318241fb67.
65. Rocha V, Labopin M, Ruggeri A, Podesta M, Gallamini A, Bonifazi F, et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation (2013) 95(10):1284-91. doi:10.1097/TP.0b013e318288ca4d.
66. Bittencourt H. Intrabone Infusion of Umbilical Cord Blood Stem Cells (NCT01711788) ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US) (2013) [updated 2013 Oct 31; cited 2013 Nov 01]. Available from: http://clinicaltrials.gov/ct2/show/NCT01711788.
67. Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P, et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood (2000) 95(3):756-68.
68. Broxmeyer HE, Kohli L, Kim CH, Lee Y, Mantel C, Cooper S, et al. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol (2003) 73(5):630-8. doi:10.1189/jlb.1002495.
69. Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood (2004) 103(8):2981-9. doi:10.1182/blood-2003-10-3611.
70. Delaney C, Ratajczak MZ, Laughlin MJ. Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol (2010) 3(3):273-83. doi:10.1586/ehm.10.24.
71. Christopherson KW II, Paganessi LA, Napier S, Porecha NK. CD26 inhibition on CD34+ or lineage-human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev (2007) 16(3):355-60. doi:10.1089/scd.2007.9996.
72. Jimenez A, Fung HC, Christopherson KW II. Cellular therapies supplement: strategies for improving transplant efficiency in the context of cellular therapeutics. Transfusion (2011) 51(Suppl 4):125S-37S. doi:10.1111/j.1537-2995.2011.03375.x.
73. Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol (2012) 40(6):445-56. doi:10.1016/j.exphem.2012.01.015.
74. Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol (2011) 12(13):1214-21. doi:10.1016/S1470-2045(11)70260-1.
75. Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2014) 123(1):133-40. doi:10.1182/blood-2013-05-506253.
76. Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood (2010) 116(15):2839-46. doi:10.1182/blood-2009-10-249219.
77. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood (2011) 118(25):6691-7. doi:10.1182/blood-2011-05-355263.
78. Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d'Histocompatibilite et d'Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. Haematologica (2013) 98(7):1154-60. doi:10.3324/haematol.2012.077685.
79. Ansari M, Uppugunduri CR, Ferrari-Lacraz S, Bittencourt H, Gumy-Pause F, Chalandon Y, et al. The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children. PLoS One (2013) 8(8):e72141. doi:10.1371/journal.pone.0072141.
80. Brunstein CG, Noreen H, DeFor TE, Maurer D, Miller JS, Wagner JE. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant (2011) 17(11):1704-8. doi:10.1016/j.bbmt.2011.04.013.
81. Sandmaier BM, Mackinnon S, Childs RW. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant (2007) 13(1 Suppl 1):87-97. doi:10.1016/j.bbmt.2006.10.015.
82. Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, et al. Prospective study of one-vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant (2012) 47(7):924-33. doi:10.1038/bmt.2011.195.
83. Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol (2011) 155(2):218-34. doi:10.1111/j.1365-2141.2011.08822.x.
84. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs (2003) 17(3):147-54. doi:10.2165/00063030-200317030-00001.
85. Chiesa R, Gilmour K, Qasim W, Adams S, Worth AJ, Zhan H, et al. Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol (2012) 156(5):656-66. doi:10.1111/j.1365-2141.2011.08994.x.
86. Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant (2011) 17(10):1460-71. doi:10.1016/j.bbmt.2011.02.001.
87. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 189(10):5082-8. doi:10.4049/jimmunol.1201964.
88. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295(5562):2097-100. doi:10.1126/science.1068440.
89. Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis (2008) 40(1):84-90. doi:10.1016/j.bcmd.2007.06.029.
90. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A. Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy (2006) 8(6):554-8. doi:10.1080/14653240601078721.
91. Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, Lee JH, et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant (2010) 45(6):1038-46. doi:10.1038/bmt.2009.304.
92. Nguyen S, Beziat V, Norol F, Uzunov M, Trebeden-Negre H, Azar N, et al. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation. Transfusion (2011) 51(8):1769-78. doi:10.1111/j.1537-2995.2010.03058.x.
93. Beck RC. Production of cytotoxic, KIR-negative NK cells from CD34+ cord blood cells with the use of Notch signaling. Transfusion (2011) 51(Suppl 4):145S-52S. doi:10.1111/j.1537-2995.2011.03377.x.
94. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One (2011) 6(6):e20740. doi:10.1371/journal.pone.0020740.
95. Tanaka J, Sugita J, Shiratori S, Shigematu A, Asanuma S, Fujimoto K, et al. Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells. Leukemia (2012) 26(5):1149-52. doi:10.1038/leu.2011.345.
96. Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, et al. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res (2010) 30(9):3493-9.
97. Tanaka J, Sugita J, Shiratori S, Shigematsu A, Imamura M. Dasatinib enhances the expansion of CD56+CD3-NK cells from cord blood. Blood (2012) 119(25):6175-6. doi:10.1182/blood-2012-03-416800.
98. Hosing C. Natural Killer (NK) Cells in Cord Blood Transplantation (NCT01619761) ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US) (2013) [cited 2013 Nov 01]. Available from: http://clinicaltrials.gov/ct2/show/NCT01619761.
99. Bao L, Cowan MJ, Dunham K, Horn B, McGuirk J, Gilman A, et al. Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections. J Immunother (2012) 35(3):293-8. doi:10.1097/CJI.0b013e31824300a2.
100. Meij P, Jedema I, van der Hoorn MA, Bongaerts R, Cox L, Wafelman AR, et al. Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica (2012) 97(8):1205-8. doi:10.3324/haematol.2011.053371.
101. Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood (2013) 121(18):3745-58. doi:10.1182/blood-2012-08-448977.
102. Clancy LE, Blyth E, Simms RM, Micklethwaite KP, Ma CK, Burgess JS, et al. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution. Biol Blood Marrow Transplant (2013) 19(5):725-34. doi:10.1016/j.bbmt.2013.01.021.
103. Geyeregger R, Freimuller C, Stevanovic S, Stemberger J, Mester G, Dmytrus J, et al. Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One (2013) 8(4):e59592. doi:10.1371/journal.pone.0059592.
104. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol (2013) 31(1):39-48. doi:10.1200/JCO.2011.39.8495.
105. Mazur MA, Davis CC, Szabolcs P. Ex vivo expansion and Th1/Tc1 maturation of umbilical cord blood T cells by CD3/CD28 costimulation. Biol Blood Marrow Transplant (2008) 14(10):1190-6. doi:10.1016/j.bbmt.2008.07.016.
106. Okas M, Gertow J, Uzunel M, Karlsson H, Westgren M, Karre K, et al. Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation. J Immunother (2010) 33(1):96-105. doi:10.1097/CJI.0b013e3181b291a4.
107. Davis CC, Marti LC, Sempowski GD, Jeyaraj DA, Szabolcs P. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. Cancer Res (2010) 70(13):5249-58. doi:10.1158/0008-5472.CAN-09-2860.
108. Park KD, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood (2006) 108(5):1770-3. doi:10.1182/blood-2005-10-006536.
109. Hanley PJ, Lam S, Shpall EJ, Bollard CM. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. J Vis Exp (2012) (63):e3627. doi:10.3791/3627.
110. Bollard C. Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus (ACT-CAT) (NCT00880789) ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US) (2013) [updated 2013 Oct 31; cited 2013 Nov 01]. Available from: http://clinicaltrials.gov/ct2/show/NCT00880789.
111. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 155(3):1151-64.
112. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med (2001) 193(11):F41-6. doi:10.1084/jem.193.11.F41.
113. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol (2001) 31(4):1247-54. doi:10.1002/1521-4141(200104)31:4<::AID-IMMU1247>3.0.CO;2-M.
114. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 4(4):330-6. doi:10.1038/ni904.
115. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299(5609):1057-61. doi:10.1126/science.1079490.
116. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet (2001) 27(1):68-73. doi:10.1038/83784.
117. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med (2007) 204(1):57-63. doi:10.1084/jem.20061852.
118. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 27(1):20-1. doi:10.1038/83713.
119. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol (2005) 35(6):1681-91. doi:10.1002/eji.200526189.
120. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol (2009) 21(10):1105-11. doi:10.1093/intimm/dxp095.
121. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+ Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 8(12):1353-62. doi:10.1038/ni1536.
122. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35-and IL-10-dependent manner. J Immunol (2009) 182(10):6121-8. doi:10.4049/jimmunol.0803646.
123. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity (2011) 34(4):566-78. doi:10.1016/j.immuni.2011.03.018.
124. Sojka DK, Fowell DJ. Regulatory T cells inhibit acute IFN-gamma synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10. Proc Natl Acad Sci U S A (2011) 108(45):18336-41. doi:10.1073/pnas.1110566108.
125. Shevach EM, Tran DQ, Davidson TS, Andersson J. The critical contribution of TGF-beta to the induction of Foxp3 expression and regulatory T cell function. Eur J Immunol (2008) 38(4):915-7. doi:10.1002/eji.200738111.
126. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol (2004) 172(8):4676-80.
127. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A (2009) 106(32):13445-50. doi:10.1073/pnas.0901944106.
128. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant (2002) 8(10):525-35. doi:10.1053/bbmt.2002.v8.pm12434947.
129. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 99(10):3493-9. doi:10.1182/blood.V99.10.3493.
130. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 196(3):389-99. doi:10.1084/jem.20020399.
131. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 9(9):1144-50. doi:10.1038/nm915.
132. Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest (2003) 112(11):1688-96. doi:10.1172/JCI17702.
133. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 104(7):2187-93. doi:10.1182/blood-2004-03-1040.
134. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 106(8):2903-11. doi:10.1182/blood-2005-03-1257.
135. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood (2006) 108(4):1291-7. doi:10.1182/blood-2006-02-003996.
136. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood (2006) 107(4):1717-23. doi:10.1182/blood-2005-06-2529.
137. Schneider M, Munder M, Karakhanova S, Ho AD, Goerner M. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Haematol (2006) 28(6):382-90. doi:10.1111/j.1365-2257.2006.00825.x.
138. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant (2010) 16(7):907-14. doi:10.1016/j.bbmt.2010.02.026.
139. Fondi C, Nozzoli C, Benemei S, Baroni G, Saccardi R, Guidi S, et al. Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol Blood Marrow Transplant (2009) 15(8):938-47. doi:10.1016/j.bbmt.2009.04.009.
140. Wolf D, Wolf AM, Fong D, Rumpold H, Strasak A, Clausen J, et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation (2007) 83(8):1107-13. doi:10.1097/01.tp.0000260140.04815.77.
141. Pabst C, Schirutschke H, Ehninger G, Bornhauser M, Platzbecker U. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res (2007) 13(10):2916-22. doi:10.1158/1078-0432.CCR-06-2602.
142. Pastore D, Delia M, Mestice A, Carluccio P, Perrone T, Gaudio F, et al. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2012) 18(6):887-93. doi:10.1016/j.bbmt.2011.10.039.
143. Delia M, Pastore D, Mestice A, Carluccio P, Perrone T, Gaudio F, et al. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience. Biol Blood Marrow Transplant (2013) 19(3):495-9. doi:10.1016/j.bbmt.2012.11.015.
144. Takahata Y, Nomura A, Takada H, Ohga S, Furuno K, Hikino S, et al. CD25+CD4+ T cells in human cord blood: an immunoregulatory subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene. Exp Hematol (2004) 32(7):622-9. doi:10.1016/j.exphem.2004.03.012.
145. Torelli GF, Maggio R, Peragine N, Chiaretti S, De Propris MS, Lucarelli B, et al. Functional analysis and gene expression profile of umbilical cord blood regulatory T cells. Ann Hematol (2012) 91(2):155-61. doi:10.1007/s00277-011-1288-y.
146. Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood (2006) 108(13):4260-7. doi:10.1182/blood-2006-06-027409.
147. Wichlan DG, Roddam PL, Eldridge P, Handgretinger R, Riberdy JM. Efficient and reproducible large-scale isolation of human CD4+ CD25+ regulatory T cells with potent suppressor activity. J Immunol Methods (2006) 315(1-2):27-36. doi:10.1016/j.jim.2006.06.014.
148. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 depletion, Treg expansion, and Treg cryopreservation. PLoS One (2008) 3(9):e3161. doi:10.1371/journal.pone.0003161.
149. Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol (2011) 23(5):679-84. doi:10.1016/j.coi.2011.06.006.
150. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood (2011) 117(14):3921-8. doi:10.1182/blood-2010-10-311894.
151. Nguyen VH, Zeiser R, Dasilva DL, Chang DS, Beilhack A, Contag CH, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood (2007) 109(6):2649-56. doi:10.1182/blood-2006-08-044529.
152. Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, et al. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model. Transfusion (2012) 52(6):1333-47. doi:10.1111/j.1537-2995.2011.03448.x.
153. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, et al. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol (2005) 115(1):3-9. doi:10.1016/j.clim.2005.02.017.
154. Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol (2009) 39(4):1088-97. doi:10.1002/eji.200838904.
155. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 105(12):4743-8. doi:10.1182/blood-2004-10-3932.
156. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 178(1):320-9.
157. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 4(6):e5994. doi:10.1371/journal.pone.0005994.
158. Asanuma S, Tanaka J, Sugita J, Kosugi M, Shiratori S, Wakasa K, et al. Expansion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells using the common gamma-chain cytokines (IL-2 and IL-15) and rapamycin. Ann Hematol (2011) 90(6):617-24. doi:10.1007/s00277-010-1121-z.
159. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 6(1):e15868. doi:10.1371/journal.pone.0015868.
160. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2011) 117(3):1061-70. doi:10.1182/blood-2010-07-293795.
161. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood (2006) 107(3):1018-23. doi:10.1182/blood-2005-07-3032.
162. Coenen JJ, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant (2007) 39(9):537-45. doi:10.1038/sj.bmt.1705628.
163. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood (2006) 108(1):390-9. doi:10.1182/blood-2006-01-0329.
164. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle (2008) 7(4):458-62. doi:10.4161/cc.7.4.5454.
165. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood (2011) 118(8):2342-50. doi:10.1182/blood-2010-10-313684.
166. Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, et al. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2009) 15(7):844-50. doi:10.1016/j.bbmt.2009.03.017.
167. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood (2010) 115(5):1098-105. doi:10.1182/blood-2009-03-207563.
168. Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, et al. DNA methylation controls Foxp3 gene expression. Eur J Immunol (2008) 38(6):1654-63. doi:10.1002/eji.200838105.
169. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood (2009) 114(18):3727-35. doi:10.1182/blood-2009-05-219584.
170. Moon C, Kim SH, Park KS, Choi BK, Lee HS, Park JB, et al. Use of epigenetic modification to induce FOXP3 expression in naive T cells. Transplant Proc (2009) 41(5):1848-54. doi:10.1016/j.transproceed.2009.02.101.
171. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood (2010) 116(1):129-39. doi:10.1182/blood-2009-12-257253.
172. Nagar M, Vernitsky H, Cohen Y, Dominissini D, Berkun Y, Rechavi G, et al. Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ T cells. Int Immunol (2008) 20(8):1041-55. doi:10.1093/intimm/dxn062.
173. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8(4):315-7. doi:10.1080/14653240600855905.
174. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol (2006) 36(10):2566-73. doi:10.1002/eji.200636416.
175. Giuliani M, Oudrhiri N, Noman ZM, Vernochet A, Chouaib S, Azzarone B, et al. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood (2011) 118(12):3254-62. doi:10.1182/blood-2010-12-325324.
176. Tobin LM, Healy ME, English K, Mahon BP. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol (2013) 172(2):333-48. doi:10.1111/cei.12056.
177. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr (2007) 13(4-5):217-26. doi:10.3727/000000006780666957.
178. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2008) 26(1):212-22. doi:10.1634/stemcells.2007-0554.
179. Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE, et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells (2013) 31(9):1980-91. doi:10.1002/stem.1432.
180. Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol (2002) 30(8):870-8. doi:10.1016/S0301-472X(02)00820-2.
181. Kim DW, Chung YJ, Kim TG, Kim YL, Oh IH. Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Blood (2004) 103(5):1941-8. doi:10.1182/blood-2003-05-1601.
182. Fei XM, Wu YJ, Chang Z, Miao KR, Tang YH, Zhou XY, et al. Co-culture of cord blood CD34(+) cells with human BM mesenchymal stromal cells enhances short-term engraftment of cord blood cells in NOD/SCID mice. Cytotherapy (2007) 9(4):338-47. doi:10.1080/14653240701291638.
183. Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, et al. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. Transfusion (2008) 48(12):2638-44. doi:10.1111/j.1537-2995.2008.01926.x.
184. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant (2009) 43(6):447-54. doi:10.1038/bmt.2008.348.
185. Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, Rico MA, Bautista G, Krsnik I, et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy (2009) 11(3):278-88. doi:10.1080/14653240902807018.
186. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant (2011) 46(2):200-7. doi:10.1038/bmt.2010.87.
187. Wu KH, Sheu JN, Wu HP, Tsai C, Sieber M, Peng CT, et al. Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. Transplantation (2013) 95(5):773-7. doi:10.1097/TP.0b013e31827a93dd.
188. Uhlin M, Sairafi D, Berglund S, Thunberg S, Gertow J, Ringden O, et al. Mesenchymal stem cells inhibit thymic reconstitution after allogeneic cord blood transplantation. Stem Cells Dev (2012) 21(9):1409-17. doi:10.1089/scd.2011.0310.
189. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 81(10):1390-7. doi:10.1097/01.tp.0000214462.63943.14.
190. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 371(9624):1579-86. doi:10.1016/S0140-6736(08)60690-X.
191. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet (1998) 20(4):394-7. doi:10.1038/3877.
192. Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood (2001) 98(7):2256-65. doi:10.1182/blood.V98.7.2256.
193. Broers AE, Posthumus-van Sluijs SJ, Spits H, van der Holt B, Lowenberg B, Braakman E, et al. Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants. Blood (2003) 102(4):1534-40. doi:10.1182/blood-2002-11-3349.
194. Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S, et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood (2003) 101(6):2294-9. doi:10.1182/blood-2002-07-2297.
195. Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL. Interleukin 7 worsens graft-versus-host disease. Blood (2002) 100(7):2642-9. doi:10.1182/blood-2002-04-1082.
196. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 29(3):313-9. doi:10.1097/01.cji.0000210386.55951.c2.
197. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 205(7):1701-14. doi:10.1084/jem.20071681.
198. Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood (2012) 120(24):4882-91. doi:10.1182/blood-2012-06-437236.
199. Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol (2013) 146(3):248-61. doi:10.1016/j.clim.2013.01.004.
200. Nadal E, Fowler A, Kanfer E, Apperley J, Goldman J, Dazzi F. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp Hematol (2004) 32(2):218-23. doi:10.1016/j.exphem.2003.10.016.
201. Inamoto Y, Fefer A, Sandmaier BM, Gooley TA, Warren EH, Petersdorf SH, et al. A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 17(9):1308-15. doi:10.1016/j.bbmt.2011.01.004.
202. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 5(179):179ra43. doi:10.1126/scitranslmed.3005265.
203. Verneris MR. T-Cell Depleted Double UCB for Refractory AML (NCT01464359) ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US) (2013) [updated 2013 Oct 31; cited 2013 Nov 01]. Available from: http://clinicaltrials.gov/ct2/show/NCT01464359.
204. Alpdogan O, Eng JM, Muriglan SJ, Willis LM, Hubbard VM, Tjoe KH, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood (2005) 105(2):865-73. doi:10.1182/blood-2003-09-3344.
205. Goldberg GL, King CG, Nejat RA, Suh DY, Smith OM, Bretz JC, et al. Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. J Immunol (2009) 182(9):5846-54. doi:10.4049/jimmunol.0801458.
206. Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med (1981) 305(12):663-7. doi:10.1056/NEJM198109173051203.
207. Kelly RM, Highfill SL, Panoskaltsis-Mortari A, Taylor PA, Boyd RL, Hollander GA, et al. Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood (2008) 111(12):5734-44. doi:10.1182/blood-2008-01-136531.
208. Murphy WJ, Durum SK, Longo DL. Role of neuroendocrine hormones in murine T cell development. Growth hormone exerts thymopoietic effects in vivo. J Immunol (1992) 149(12):3851-7.
209. Chen BJ, Cui X, Sempowski GD, Chao NJ. Growth hormone accelerates immune recovery following allogeneic T-cell-depleted bone marrow transplantation in mice. Exp Hematol (2003) 31(10):953-8. doi:10.1016/S0301-472X(03)00196-6.
210. Chen BJ, Deoliveira D, Spasojevic I, Sempowski GD, Jiang C, Owzar K, et al. Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates. PLoS One (2010) 5(6):e11056. doi:10.1371/journal.pone.0011056.
211. Kooijman R, Scholtens LE, Rijkers GT, Zegers BJ. Type I insulin-like growth factor receptor expression in different developmental stages of human thymocytes. J Endocrinol (1995) 147(2):203-9. doi:10.1677/joe.0.1470203.
212. Alpdogan O, Muriglan SJ, Kappel BJ, Doubrovina E, Schmaltz C, Schiro R, et al. Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation (2003) 75(12):1977-83. doi:10.1097/01.TP.0000070167.81584.A2.
213. Min D, Taylor PA, Panoskaltsis-Mortari A, Chung B, Danilenko DM, Farrell C, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood (2002) 99(12):4592-600. doi:10.1182/blood.V99.12.4592.
214. Rossi S, Blazar BR, Farrell CL, Danilenko DM, Lacey DL, Weinberg KI, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood (2002) 100(2):682-91. doi:10.1182/blood.V100.2.682.
215. Min D, Panoskaltsis-Mortari A, Kuro OM, Hollander GA, Blazar BR, Weinberg KI. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood (2007) 109(6):2529-37. doi:10.1182/blood-2006-08-043794.
216. Rossi SW, Jeker LT, Ueno T, Kuse S, Keller MP, Zuklys S, et al. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood (2007) 109(9):3803-11. doi:10.1182/blood-2006-10-049767.
217. Wang Y, Chen G, Qiao S, Ma X, Tang X, Sun A, et al. Keratinocyte growth factor enhanced immune reconstitution in murine allogeneic umbilical cord blood cell transplant. Leuk Lymphoma (2011) 52(8):1556-66. doi:10.3109/10428194.2011.573037.
218. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood (2006) 108(9):3216-22. doi:10.1182/blood-2006-04-017780.
219. Rizwan R, Levine JE, Defor T, Ferarra JL, Weisdorf DJ, Blazar BR, et al. Peritransplant palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation. Am J Hematol (2011) 86(10):879-82. doi:10.1002/ajh.22136.
220. Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR, et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant (2013) 48(1):99-104. doi:10.1038/bmt.2012.115.
221. Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant (2008) 14(9):1017-21. doi:10.1016/j.bbmt.2008.06.013.
222. Kenins L, Gill JW, Boyd RL, Hollander GA, Wodnar-Filipowicz A. Intrathymic expression of Flt3 ligand enhances thymic recovery after irradiation. J Exp Med (2008) 205(3):523-31. doi:10.1084/jem.20072065.
223. Wils EJ, Braakman E, Verjans GM, Rombouts EJ, Broers AE, Niesters HG, et al. Flt3 ligand expands lymphoid progenitors prior to recovery of thymopoiesis and accelerates T cell reconstitution after bone marrow transplantation. J Immunol (2007) 178(6):3551-7.
224. Fewkes NM, Krauss AC, Guimond M, Meadors JL, Dobre S, Mackall CL. Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation. Blood (2010) 115(20):4120-9. doi:10.1182/blood-2009-10-248898.
225. Kelly RM, Goren EM, Taylor PA, Mueller SN, Stefanski HE, Osborn MJ, et al. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood (2010) 115(5):1088-97. doi:10.1182/blood-2009-05-223198.
226. Merindol N, Charrier E, Duval M, Soudeyns H. Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. J Leukoc Biol (2011) 90(1):49-60. doi:10.1189/jlb.0111007.